Biomedical Engineering Reference
In-Depth Information
112. Tang L, Eaton JW (1995) Inflammatory responses to biomaterials. Am J Clin Pathol
103(4):466-471
113. Tang L, Hu W (2005) Molecular determinants of biocompatibility. Expert Rev Med Devices
2(4):493-500
114. Tanner KE (2010) Bioactive composites for bone tissue engineering. Proc Inst Mech Eng H
224(12):1359-1372
115. Terasaki K, Kanzaki T, Aoki T, Iwata K, Saiki I (2003) Effects of recombinant human tissue
inhibitor of metalloproteinases-2 (rh-TIMP-2) on migration of epidermal keratinocytes
in vitro and wound healing in vivo. J Dermatol 30(3):165-172
116. Thevenot P, Hu W, Tang L (2008) Surface chemistry influences implant biocompatibility.
Curr Top Med Chem 8(4):270-280
117. Underwood CK, Min D, Lyons JG, Hambley TW (2003) The interaction of metal ions and
Marimastat with matrix metalloproteinase 9. J Inorg Biochem 95(2-3):165-170
118. Vaalamo M, Leivo T, Saarialho-Kere U (1999) Differential expression of tissue inhibitors of
metalloproteinases (TIMP-1 -2 -3 and -4) in normal and aberrant wound healing. Hum Pathol
30(7):795-802
119. Velasco G, Pendas AM, Fueyo A, Knauper V, Murphy G, Lopez-Otin C (1999) Cloning and
characterization of human MMP-23 a new matrix metalloproteinase predominantly expressed
in reproductive tissues and lacking conserved domains in other family members. J Biol Chem
274(8):4570-4576
120. Willenbrock F, Murphy G, Phillips IR, Brocklehurst K (1995) The second zinc atom in the
matrix metalloproteinase catalytic domain is absent in the full-length enzymes: a possible
role for the C-terminal domain. FEBS Lett 358(2):189-192
121. Woessner JF Jr (1994) The family of matrix metalloproteinases. Ann N Y Acad Sci 732:11-21
122. Woessner JF Jr (2001) That impish TIMP: the tissue inhibitor of metalloproteinases-3. J Clin
Invest 108(6):799-800
123. Wolber G, Langer T (2005) LigandScout: 3-D pharmacophores derived from protein-bound
ligands and their use as virtual screening filters. J Chem Inf Model 45(1):160-169
124. Wolber G, Seidel T, Bendix F, Langer T (2008) Molecule-pharmacophore superpositioning
and pattern matching in computational drug design. Drug Discov Today 13(1-2):23-29
125. Zhang W, Hou TJ, Qiao XB, Huai S, Xu XJ (2004) Binding affinity of hydroxamate inhibi-
tors of matrix metalloproteinase-2. J Mol Model 10(2):112-120
126. Zohny SF, Fayed ST (2010) Clinical utility of circulating matrix metalloproteinase-7 (MMP-
7) CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for
diagnosis of epithelial ovarian cancer. Med Oncol 27(4):1246-1253
127. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE et al (1998) Tissue inhibi-
tor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor
membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 273(2):1216-1222
Search WWH ::
Custom Search